DARIFENACIN, THE FIRST SELECTIVE M3 ANTAGONIST FOR OVERACTIVE BLADDER: COMPARISON WITH OXYBUTYNIN ON AMBULATORY URODYNAMIC MONITORING AND SALIVARY FLOW
AR Mundy1, P Abrams2, CR Chapple3, DE Neal4.
1Institute of Urology, 2Bristol Urological Institute, 3Royal Hallamshire Hospital, 4The Freeman Hospital.
City & Country: 1London, 2Bristol, 3Sheffield, 4Newcastle, UK.
|
Abstract 221
|
|
Non Discussion Poster
Scientific Non Discussion Poster Session 17
|
|